426 related articles for article (PubMed ID: 23147664)
1. Medical therapies for hepatocellular carcinoma: a critical view of the evidence.
Villanueva A; Hernandez-Gea V; Llovet JM
Nat Rev Gastroenterol Hepatol; 2013 Jan; 10(1):34-42. PubMed ID: 23147664
[TBL] [Abstract][Full Text] [Related]
2. Medical treatment of hepatocellular carcinoma.
Germano D; Tinessa V; Barletta E; Cannella L; Daniele B
Minerva Med; 2013 Oct; 104(5):545-61. PubMed ID: 24101112
[TBL] [Abstract][Full Text] [Related]
3. Systemic therapy of hepatocellular carcinoma: current status and future perspectives.
Germano D; Daniele B
World J Gastroenterol; 2014 Mar; 20(12):3087-99. PubMed ID: 24696596
[TBL] [Abstract][Full Text] [Related]
4. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman OM; Elsayed Z
Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma review: current treatment, and evidence-based medicine.
Raza A; Sood GK
World J Gastroenterol; 2014 Apr; 20(15):4115-27. PubMed ID: 24764650
[TBL] [Abstract][Full Text] [Related]
6. Advances in managing hepatocellular carcinoma.
Reataza M; Imagawa DK
Front Med; 2014 Jun; 8(2):175-89. PubMed ID: 24810646
[TBL] [Abstract][Full Text] [Related]
7. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
[TBL] [Abstract][Full Text] [Related]
8. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
9. [Hepatocellular Carcinoma: therapeutic options 2015].
Schultheiß M; Bettinger D; Neeff HP; Brunner TB; Thimme R
Dtsch Med Wochenschr; 2015 Jul; 140(14):1063-8. PubMed ID: 26182255
[TBL] [Abstract][Full Text] [Related]
10. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
Eggert T; Greten TF
Digestion; 2017; 96(1):1-4. PubMed ID: 28605745
[TBL] [Abstract][Full Text] [Related]
11. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
[TBL] [Abstract][Full Text] [Related]
12. Newer treatments for advanced hepatocellular carcinoma.
Song MJ; Bae SH
Korean J Intern Med; 2014 Mar; 29(2):149-55. PubMed ID: 24648795
[TBL] [Abstract][Full Text] [Related]
13. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
Peng Z; Chen S; Wei M; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Chen M; Qian G; Kuang M
Radiology; 2018 May; 287(2):705-714. PubMed ID: 29390197
[TBL] [Abstract][Full Text] [Related]
14. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
Sacco R; Antonucci M; Bargellini I; Marceglia S; Mismas V; Cabibbo G
Future Oncol; 2015; 11(17):2371-3. PubMed ID: 26270206
[No Abstract] [Full Text] [Related]
15. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hepatocellular carcinoma: beyond international guidelines.
Sangiovanni A; Colombo M
Liver Int; 2016 Jan; 36 Suppl 1():124-9. PubMed ID: 26725909
[TBL] [Abstract][Full Text] [Related]
17. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.
Burak KW; Thomas MB; Zhu AX
HPB (Oxford); 2010 Jun; 12(5):321-2. PubMed ID: 20590906
[No Abstract] [Full Text] [Related]
18. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Geschwind JF; Chapiro J
Clin Adv Hematol Oncol; 2016 Aug; 14(8):585-7. PubMed ID: 27487101
[No Abstract] [Full Text] [Related]
19. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.
Cabibbo G; Tremosini S; Galati G; Mazza G; Gadaleta-Caldarola G; Lombardi G; Antonucci M; Sacco R
Expert Rev Anticancer Ther; 2014 Jul; 14(7):831-45. PubMed ID: 24850249
[TBL] [Abstract][Full Text] [Related]
20. The emerging questionable benefit of sorafenib as a neo-adjuvant in HCC patients treated with Y-90 radioembolization pending liver transplantation.
Shouval D
J Hepatol; 2014 Aug; 61(2):190-2. PubMed ID: 24845608
[No Abstract] [Full Text] [Related]
[Next] [New Search]
